Source: International Congress 2015 – Different data in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Olga Shtepa (Dnipropetrovsk, Ukraine), Olga Shtepa, Tetyana Pertseva, Tetyana Kireyeva. Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes. Eur Respir J 2015; 46: Suppl. 59, 3672

Member's Comments

No comment yet.

Related content which might interest you: Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Co-morbidity and hospitalization rate in patients (pts) with acute exacerbation (AE) of COPD Source: International Congress 2015 – Different data in COPD Year: 2015 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Vascular-platelet hemostasis parameters in the stable phase and in acute exacerbation (AE) of COPD Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Implications of under treatment of stable COPD (SAVING study) Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Heterogeneity inside group D COPD patients: About 827 cases Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 The role of biomarkers in predicting outcomes in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU Year: 2013 Vitamin D, exacerbations and hospitalizations in COPD patients Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Characteristics and prognostic factors associated with cardiovascular (CV) comorbidity in COPD patients hospitalized for acute exacerbation (AECOPD) Source: Annual Congress 2013 –COPD mechanisms Year: 2013 CAT in COPD phenotypes (POPE study) Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016